In my opinion ANYTHING can happen from now to then and the aim for the study was 120 originally ... DSMB can “modify” depending on several factors outline there... “background of testing agent” is one of those reasons... As Dr. J said, this is NOT a “new peptide” but of course it’s the first time this medicine is being used for this purpose... He has the medical lingo to explain that better than me...
I see this frenzied COVID rush ..... very urgent... President fast-tracking vaccine and treatments .... Wants to get stuff in and approved before election. Being that this has plenty of evidence for being “safe” and some evidence for futility (yes more data needed, and here’s the “28 day talk” that effed with the SP)... I simply still see this moving quickly, given the situation and for the reasons I listed there... This thing isn’t new under the sun. Shows some efficacy, safe, meets EUA criteria....
As Mr. J Belfort mentioned in here.... The path seems to be toward a BUYOUT. Even NeuroRx....Dr. Javitt’s first company was bought... Don’t you guys think Pfizer, J&J, Moderna, whomever, have eyes on these things??? This is about the biggest no-brainer, imo.... Vaccine will be great BUT this sounds like a safe treatment that might need to be coupled with the vaccine for many of the reasons Dr. Yo mentioned yesterday.
Re: uplisting, all Dr. J said is that investors need to continue to have interest in the stock... He didn’t say it needs to “sky rocket.” Yes we NEED funding from GEM (which we got, all topped up, great) and we NEED so many shareholders on record for Nasdaq, plus $4 a share. I am reading between the lines and I think this is looking very good. I can see a couple different ways of hitting $4 with a buyout coming after we are up on the Nas....
IMO as always!!
$RLFTF
AI
Market Data 
Markets 
